Page 47 - TD-3-3

Tumor Discovery LncRNA HA117 in osteosarcoma regulation

32. Li B, Dewey CN. RSEM: Accurate transcript quantification therapeutic value of exosomes in cancer metastasis. Mol
from RNA-Seq data with or without a reference genome. Cancer. 2019;18(1):53.
BMC Bioinformatics. 2011;12:323.
doi: 10.1186/s12943-019-0964-8
doi: 10.1186/1471-2105-12-323 44. Sha L, Ma D, Chen C. Exosome-mediated Hic-5
33. Robinson MD, McCarthy DJ, Smyth GK. edgeR: regulates proliferation and apoptosis of osteosarcoma
A Bioconductor package for differential expression via Wnt/β-catenin signal pathway. Aging (Albany NY).
analysis of digital gene expression data. Bioinformatics. 2020;12(23):23598-23608.
2010;26(1):139-140.
doi: 10.18632/aging.103546
doi: 10.1093/bioinformatics/btp616
45. Jiang M, Jike Y, Liu K, et al. Exosome-mediated miR-144-3p
34. Li J, Ma W, Zeng P, et al. LncTar: A tool for predicting the promotes ferroptosis to inhibit osteosarcoma proliferation,
RNA targets of long noncoding RNAs. Brief Bioinform. migration, and invasion through regulating ZEB1. Mol
2015;16(5):806-812. Cancer. 2023;22(1):113.
doi: 10.1093/bib/bbu048 doi: 10.1186/s12943-023-01804-z
35. Shannon P, Markiel A, Ozier O, et al. Cytoscape: A software 46. Lindström MS. Elucidation of motifs in ribosomal protein
environment for integrated models of biomolecular S9 that mediate its nucleolar localization and binding to
interaction networks. Genome Res. 2003;13(11):2498-2504. NPM1/nucleophosmin. PLoS One. 2012;7(12):e52476.
doi: 10.1101/gr.1239303 doi: 10.1371/journal.pone.0052476
36. Gillespie M, Jassal B, Stephan R, et al. The reactome 47. Lindström MS, Zhang Y. Ribosomal protein S9 is a novel
pathway knowledgebase 2022. Nucleic Acids Res. B23/NPM-binding protein required for normal cell
2022;50(D1):D687-D692. proliferation. J Biol Chem. 2008;283(23):15568-15576.
doi: 10.1093/nar/gkab1028 doi: 10.1074/jbc.M801151200
37. Sherman BT, Hao M, Qiu J, et al. DAVID: A web server 48. Cheng DD, Zhu B, Li SJ, Yuan T, Yang QC, Fan CY. Down-
for functional enrichment analysis and functional regulation of RPS9 inhibits osteosarcoma cell growth
annotation of gene lists (2021 update). Nucleic Acids Res. through inactivation of MAPK signaling pathway. J Cancer.
2022;50(W1):W216-W221. 2017;8(14):2720-2728.
doi: 10.1093/nar/gkac194 doi: 10.7150/jca.19130
38. Ito K, Murphy D. Application of ggplot2 to pharmacometric 49. Li S, Hu T, Yuan T, Cheng D, Yang Q. Nucleoside diphosphate
graphics. CPT Pharmacometrics Syst Pharmacol. kinase B promotes osteosarcoma proliferation through
2013;2(10):e79. c-Myc. Cancer Biol Ther. 2018;19(7):565-572.
doi: 10.1038/psp.2013.56 doi: 10.1080/15384047.2017.1416273
39. Gyorffy B, Lánczky A, Szállási Z. Implementing an online 50. Feng XT, Wang C, Zhang FJ, Wu XQ, Zhang Z. MicroRNA-
tool for genome-wide validation of survival-associated 1274a serves as a prognostic biomarker in patients with
biomarkers in ovarian-cancer using microarray data from osteosarcoma and is involved in tumor progression
1287 patients. Endocr Relat Cancer. 2012;19(2):197-208. via targeting ADAM9. J Biol Regul Homeost Agents.
2021;35(1):151-160.
doi: 10.1530/erc-11-0329
doi: 10.23812/20-695-a
40. Love MI, Huber W, Anders S. Moderated estimation of
fold change and dispersion for RNA-seq data with DESeq2. 51. Zhao R, Chen S, Cui W, et al. PTPN1 is a prognostic
Genome Biol. 2014;15(12):550. biomarker related to cancer immunity and drug sensitivity:
From pan-cancer analysis to validation in breast cancer.
doi: 10.1186/s13059-014-0550-8
Front Immunol. 2023;14:1232047.
41. McAndrews KM, Kalluri R. Mechanisms associated with doi: 10.3389/fimmu.2023.1232047
biogenesis of exosomes in cancer. Mol Cancer. 2019;18(1):52.
52. Glubb DM, Maranian MJ, Michailidou K, et al. Fine-scale
doi: 10.1186/s12943-019-0963-9
mapping of the 5q11.2 breast cancer locus reveals at least
42. Syn NL, Wang L, Chow EK, Lim CT, Goh BC. Exosomes in three independent risk variants regulating MAP3K1. Am J
cancer nanomedicine and immunotherapy: Prospects and Hum Genet. 2015;96(1):5-20.
challenges. Trends Biotechnol. 2017;35(7):665-676.
doi: 10.1016/j.ajhg.2014.11.009
doi: 10.1016/j.tibtech.2017.03.004
53. Cuevas BD, Winter-Vann AM, Johnson NL,
43. Wu M, Wang G, Hu W, Yao Y, Yu XF. Emerging roles and Johnson GL. MEKK1 controls matrix degradation and tumor

Volume 3 Issue 3 (2024) 13 doi: 10.36922/td.3670